

## PRESS RELEASE

---

Date: November 13, 2018  
From: Microlife Corporation  
Subject: Completion of Acquisition of Microlife Corporation by Midas Investment

---

Taipei – November 13, 2018: Microlife Corporation (“Microlife”) today announced the completion of the acquisition of Microlife by Midas Investment Company Limited (“Midas Investment”) Shares of Microlife will be delisted from the Taiwan Stock Exchange effective November 13, 2018.

Midas Investment (滿德投資) is a 50/50 joint venture set up between Morgan Stanley Private Equity Asia (or North Haven Private Equity Asia) and Midas Fund LP for the purpose of acquiring 100% ownership in Microlife. Founded in 1981 by Mr. Kin Yuan Lin, and listed on the Taipei Exchange in 2001, Microlife is a leading global consumer medical device company with over 3,000 employees globally. With a successful and consistent track record of producing high quality consumer medical devices such as thermometers and blood pressure monitors, Microlife commands significant market share in several of its product categories, especially in the US and Europe. Underpinning Microlife’s success is its strong R&D capabilities and extensive international distribution network. Microlife’s unique capability in combining electronic digital technology know-how with medical domain knowledge to design clinically validated home-use medical devices is further evidenced by the awards and endorsements it has received from leading global institutions such as the National Health Service of the United Kingdom and Red Dot Design. Microlife’s international distribution network covers over 90 countries globally through its own direct sales force and distributor network.

Mr. Andrew Hawkyard, a Managing Director of Morgan Stanley Private Equity Asia and a director of Midas Investment, said, “We are honored to be taking on the stewardship of Microlife, and we have the highest respect for its management team, global distribution partners and employees who have built Microlife into a preeminent global consumer medical device company.”

Mr. Sean Fang, managing partner of Midas Fund LP and a director of Midas Investment, said, “We look forward to the opportunity to accelerate Microlife’s growth on the strong foundation built by its founder, Mr. KY Lin. Microlife’s management team, employees and partners are an integral part of this exciting vision.”

Mr. KY Lin, said, “Since founding the company nearly 40 years ago, I am proud to see what Microlife has become. I am also pleased to hand over the business to the new shareholders who through our long discussions over the years share a common vision for Microlife. I am highly confident that the business will continue to flourish under their stewardship. As for me, I look forward to a long overdue break and to pursue other personal interests post hand over.”

Mr. William Hsu, CEO-designate post deal completion, further added, “With the backing from the new group of global professional investors, we will continue to invest in our

core competency in developing cutting edge research and technology, and delivering high quality and innovative medical devices to our customers. I am extremely excited to lead Microlife to the next growth phase. The management team, together with our employees and global partners, are also highly motivated to take Microlife to a new level.”

#### About Morgan Stanley Private Equity Asia

Morgan Stanley Private Equity Asia has been managing private equity funds focused on investing in Asia for over 20 years and has offices in various cities across the Asia region including Hong Kong, Beijing, Shanghai, Seoul and Mumbai.

#### About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing investment banking, securities, wealth management and investment management services. With offices in more than 43 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For more information about Morgan Stanley, please visit [www.morganstanley.com](http://www.morganstanley.com). “

#### **For enquiries from, please contact:**

Microlife Corporation

Phone: 886-2-8797-1288

Email: [ir-service@microlife.com.tw](mailto:ir-service@microlife.com.tw)